TENX Research | Milton Maxwell

TENX

Tenax Therapeutics, Inc.

11.16

+0.55+5.18%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

69.68M

P/E (TTM)

Basic EPS (TTM)

-0.74

Dividend Yield

Recent Filings

10-K

3/10/26Mar 10, 2026

8-K

3/10/26Mar 10, 2026

8-K

1/9/26Jan 9, 2026

8-K

12/17/25Dec 17, 2025

10-Q

Q3 FY2025 results

11/12/25Nov 12, 2025

Tenax Therapeutics ramped R&D expenses to $10.3M in Q3 ended September 30, 2025, up 232% y/y from $3.1M, driving operating loss to $16.8M (vs $4.6M y/y) and net loss to $15.8M after $1.0M interest income. Nine-month net loss hit $37.1M on $39.9M operating expenses, 227% y/y higher, fueled by Phase 3 LEVEL trial acceleration and stock comp. Cash swelled to $99.4M, bolstered by $23.2M March 2025 offering net proceeds; operating cash burn was $22.4M. Cash funds operations through 2027. License amended September 3, 2025 for worldwide oral levosimendan rights. Warrants overhang dilution risk.

About

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

CEO

Mr. Christopher T. Giordano

IPO

4/4/1994

Website

https://www.tenaxthera.com

Employees

Sector

Healthcare

Industry

Biotechnology